` PPBT (Purple Biotech Ltd) vs S&P 500 Comparison - Alpha Spread

PPBT
vs
S&P 500

Over the past 12 months, PPBT has underperformed S&P 500, delivering a return of -75% compared to the S&P 500's 9% growth.

Stocks Performance
PPBT vs S&P 500

Loading
PPBT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
PPBT vs S&P 500

Loading
PPBT
S&P 500
Difference
www.alphaspread.com

Performance By Year
PPBT vs S&P 500

Loading
PPBT
S&P 500
Add Stock

Competitors Performance
Purple Biotech Ltd vs Peers

S&P 500
PPBT
LLY
JNJ
NOVO B
ROG
Add Stock

Purple Biotech Ltd
Glance View

Market Cap
82.2m USD
Industry
Pharmaceuticals

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

PPBT Intrinsic Value
2.6116 USD
Undervaluation 7%
Intrinsic Value
Price
P
Back to Top